Scholar Rock Announces Issuance of U.S. Patent Broadly Relevant to Antibodies that Modulate TGFβ Activation
09 April 2020 - 9:30PM
Business Wire
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical
company focused on the treatment of serious diseases in which
protein growth factors play a fundamental role, today announced
that the United States Patent Office (USPTO) issued U.S. Patent No.
10,597,443 with an expiry of May 2034. This patent broadly covers
methods for making activation modulators of TGFβ that utilize
Scholar Rock’s proprietary platform approach of targeting the
precursor form of growth factors.
“We are pleased with this important addition to our patent
portfolio as it further differentiates our leadership position in
the development of antibodies that modulate signaling of TGFβ
isoforms,” said Nagesh Mahanthappa, Ph.D., President and CEO of
Scholar Rock. “TGFβ is a key driver of a number of disease-relevant
processes, including fibrosis and immune system evasion by cancer
cells, for which we have discovered highly potent and selective
inhibitors of TGFβ1 activation. Notably, this patent covers
SRK-181, our product candidate being developed for the treatment of
cancers resistant to checkpoint inhibitor therapy, such as
anti-PD-(L)1 antibodies.”
The issued claims are directed to manufacture methods that
include selection of modulators that specifically bind a large
latent complex antigen of TGFβ isoforms. This broadly relates to
TGFβ activation inhibitors that are specific to the context of
presenting molecules, such as GARP and LTBP, as well as activation
inhibitors that are not dependent on a specific presenting
molecule. The latter class of antibodies includes our cancer
immunotherapy clinical product candidate, SRK-181, being developed
to expand the number of patients who could benefit from checkpoint
inhibitor therapies.
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company
focused on the discovery and development of innovative medicines
for the treatment of serious diseases in which signaling by protein
growth factors plays a fundamental role. Scholar Rock is creating a
pipeline of novel product candidates with the potential to
transform the lives of patients suffering from a wide range of
serious diseases, including neuromuscular disorders, cancer,
fibrosis and anemia. Scholar Rock’s newly elucidated understanding
of the molecular mechanisms of growth factor activation enabled it
to develop a proprietary platform for the discovery and development
of monoclonal antibodies that locally and selectively target these
signaling proteins at the cellular level. By developing product
candidates that act in the disease microenvironment, the Company
intends to avoid the historical challenges associated with
inhibiting growth factors for therapeutic effect. Scholar Rock
believes its focus on biologically validated growth factors may
facilitate a more efficient development path. For more information,
please visit www.ScholarRock.com or follow Scholar Rock on Twitter
(@ScholarRock) and LinkedIn
(https://www.linkedin.com/company/scholar-rock/).
Scholar Rock® is a registered trademark of Scholar Rock,
Inc.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding Scholar
Rock’s future expectations, plans and prospects, including without
limitation, Scholar Rock’s expectations regarding its growth,
strategy, progress; IP strategy; and timing of its clinical trials
for SRK-015, SRK-181, and other product candidates. The use of
words such as “may,” “might,” “will,” “should,” “expect,” “plan,”
“anticipate,” “believe,” “estimate,” “project,” “intend,” “future,”
“potential,” or “continue,” and other similar expressions are
intended to identify such forward-looking statements. All such
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include
Scholar Rock’s ability to provide the financial support, resources
and expertise necessary to identify and develop product candidates
on the expected timeline; competition from third parties that are
developing products for similar uses; Scholar Rock’s ability to
obtain, maintain and protect its intellectual property; and those
risks more fully discussed in the section entitled "Risk Factors"
in Scholar Rock’s Annual Report on Form 10-K for the year ended
December 31, 2019, as well as discussions of potential risks,
uncertainties, and other important factors in Scholar Rock’s
subsequent filings with the Securities and Exchange Commission. Any
forward-looking statements represent Scholar Rock’s views only as
of today and should not be relied upon as representing its views as
of any subsequent date. All information in this press release is as
of the date of the release, and Scholar Rock undertakes no duty to
update this information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200409005199/en/
Scholar Rock Contact: Investors/Media Catherine Hu
chu@scholarrock.com 917-601-1649 Media Contact: The Yates
Network Kathryn Morris kathryn@theyatesnetwork.com 914-204-6412
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jul 2023 to Jul 2024